Gainers

  • Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 147.2% to $0.67 during Wednesday's pre-market session. The company's market cap stands at $1.0 million. The company's, Q1 earnings came out 3 days ago.
  • Jupiter Neurosciences (NASDAQ:JUNS) stock increased by 106.25% to $0.66. The market value of their outstanding shares is at $11.6 million. As per the news, the Q1 earnings report came out 4 days ago.
  • BiomX (AMEX:PHGE) shares increased by 41.76% to $0.53. The company's market cap stands at $3.7 million.
  • Immunovant (NASDAQ:IMVT) stock rose 28.18% to $33.7. The company's market cap stands at $5.3 billion. As per the news, the Q4 earnings report came out today.
  • China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 12.9% to $1.75. The market value of their outstanding shares is at $6.9 million.
  • OmniAb (NASDAQ:OABI) stock moved upwards by 10.97% to $2.63. The market value of their outstanding shares is at $343.5 million.

Losers

  • Annovis Bio (NYSE:ANVS) stock fell 17.5% to $1.6 during Wednesday's pre-market session. The market value of their outstanding shares is at $67.2 million. The company's, Q1 earnings came out 3 days ago.
  • Virax Biolabs Group (NASDAQ:VRAX) stock declined by 17.49% to $0.25. The company's market cap stands at $2.2 million.
  • Sunshine Biopharma (NASDAQ:SBFM) stock decreased by 17.26% to $0.36. The company's market cap stands at $2.2 million.
  • Wellgistics Health (NASDAQ:WGRX) shares declined by 16.55% to $0.14. The market value of their outstanding shares is at $21.2 million. The company's, Q1 earnings came out yesterday.
  • Purple Biotech (NASDAQ:PPBT) shares declined by 14.82% to $2.99. The company's market cap stands at $3.2 million. As per the press release, Q1 earnings came out 3 days ago.
  • GlucoTrack (NASDAQ:GCTK) shares decreased by 13.47% to $0.48. The company's market cap stands at $2.0 million. As per the press release, Q1 earnings came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.